

DAFTAR PUSTAKA

- Acan, D., Calan, M., Er, D., et al. 2018. "The prevalence and systemic risk factors of diabetic macular edema: A cross-sectional study from Turkey". *BMC Ophthalmol*, 18(1): 1–8.
- Amrani, D.L. 1990. "Regulation of fibrinogen biosynthesis". *Blood Coagulation & Fibrinolysis*, 1(5): 443–446.
- Ariens, R.A.S. 2002. "Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms". *Blood*, 100(3): 743–754.
- Ascaso, F.J., Huerva, V. & Grzybowski, A. 2014. "The Role of Inflammation in the Pathogenesis of Macular Edema Secondary to Retinal Vascular Diseases". *Mediators of Inflammation*, 2014: 1–6.
- Augustin, A., Loewenstein, A. & Kuppermann, B.D. 2010. "General pathophysiology". In *Macular Edema: A Practical Approach*. 10–26.
- Badan Penelitian dan Pengembangan Kesehatan. 2008. "Riset Kesehatan Dasar (RISKESDAS) 2007". *Laporan Nasional 2007*: 1–384.
- Bahrami, B., Zhu, M., Hong, T., et al. 2016. "Diabetic macular oedema: pathophysiology, management challenges and treatment resistance". *Diabetologia*, 59(8): 1594–1608.
- Bastaki, S. 2005. "Review Diabetes mellitus and its treatment". *Int J Diabetes & Metabolism*, 13: 111–134.
- Bhagat, N., Grigorian, R.A., Tutela, A., et al. 2009. "Diabetic Macular Edema: Pathogenesis and Treatment". *Surv Ophthalmol*, 54(1): 1–32.
- Bird, A.C. & Bok, D. 2018. "Why the macula?". *Eye*, 32(5): 858–862.
- Bo, M., Raspo, S., Morra, F., et al. 2004. "Body fat is the main predictor of fibrinogen levels in healthy non-obese men". *Metabolism*, 53(8): 984–988.
- Brody, D.C., Syroka, J. & Zervos, M. 2002. "Dynamical pricing of weather derivatives". *Quantitative Finance*, 2(3): 189–198.
- Ceriello, A. 1993. "Coagulation activation in diabetes mellitus: The role of hyperglycaemia and therapeutic prospects". *Diabetologia*, 36(11): 1119–1125.
- Chavakis, T., Bierhaus, A. & Nawroth, P.P. 2004. "RAGE (receptor for advanced glycation end products): a central player in the inflammatory response". *Microbes and Infection / Institut Pasteur*, 6(13): 1219–25.
- Chawla, A., Chawla, R. & Jaggi, S. 2016. "Microvascular and macrovascular

- complications in diabetes mellitus: Distinct or continuum?". *Indian J Endocrinol and Metab*, 20(4): 546.
- Chou, T.-H., Wu, P.-C., Kuo, J.Z.-C., et al. 2009. "Relationship of diabetic macular oedema with glycosylated haemoglobin". *Eye*, 23(6): 1360–1363.
- Chovatiya, R. & Medzhitov, R. 2014. "Stress, inflammation, and defense of homeostasis". *Molecular Cell*, 54(2): 281–288.
- Ciulla, T.A., Amador, A.G. & Zinman, B. 2003. "Diabetic retinopathy and diabetic macular edema: Pathophysiology, screening, and novel therapies". *Diabetes Care*, 26(9): 2653–2664.
- Congdon, N., Zheng, Y. & He, M. 2012. "The worldwide epidemic of diabetic retinopathy". *Indian J Ophthalmol*, 60(5): 428.
- Coscas, G., Cunha-Vaz, J. & Soubrane, G. 2010. "Macular Edema: Definition and basic concepts". *Dev Ophthalmol*, 47: 1–9.
- Cunha-Vaz, J. 1998. "Diabetic macular edema". *Eur J Ophthalmol*, 8(3): 127–130.
- Cunha-Vaz, J., Ashton, P., Iezzi, R., et al. 2014. "Sustained Delivery Fluocinolone Acetonide Vitreous Implants". *Ophthalmology*, 121(10): 1892–1903.e3.
- Daruich, A., Matet, A., Moulin, A., et al. 2018. "Mechanisms of macular edema: Beyond the surface". *Prog Retin Eye Res*, 63(October): 20–68.
- Das, A., Mcguire, P.G. & Rangasamy, S. 2015. "Diabetic Macular Edema : Pathophysiology and Novel Therapeutic Targets". *Ophthalmology*, (1): 1–20.
- Davalos, D. & Akassoglou, K. 2012. "Fibrinogen as a key regulator of inflammation in disease". *Semin Immunopathol*, 34(1): 43–62.
- Demirci, H., Erdamar, H., Toruner, F.B., et al. 2007. "Association Between Serum Fibrinogen Levels and Diabetic Microvascular Complications in Type 2 Diabetes Mellitus". , 17(6): 306–308.
- Denis, U., Lecomte, M., Paget, C., et al. 2002. "Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture: Involvement of diacylglycerol/ceramide production and oxidative stress induction". *Free Radic Biol Med*, 33(2): 236–247.
- Dhawale, S. 2015. "Association between Serum Fibrinogen Level in Type-2 Diabetes Mellitus Patient with or without Microvascular Complication". , 1(9): 555–561.
- Diabetes, D.O.F. 2010. "Diagnosis and Classification of Diabetes Mellitus". *Diabetes Care*, 33(Supplement_1): S62–S69.
- Ditschuneit, H.H., Flechtner-Mors, M. & Adler, G. 1995. "Fibrinogen in Obesity

- Before and After Weight Reduction". *Obes Res*, 3(1): 43–48.
- Eltahir, M.M., Abdelgadir, E.A., Abdalla, S.E., et al. 2015. "Coagulation State in Diabetic Retinopathy in Type 2 Diabetic Sudanese Patients". *J Clin Pathol*, 1(2): 17–24.
- Folson, A., Qamieh, H., Falck, J., et al. 1993. "Plasma fibrinogen: levels and correlates in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) Study". *AM J Epidemiol*, 138(12): 1023–36.
- Fong, D.S., Aiello, L., Gardner, T.W., et al. 2004. "Retinopathy in Diabetes". *Diabetes Care*, 27(Supplement 1): S84–S87.
- Fowler, M.J. 2008. "Microvascular and Macrovascular Complications of Diabetes". *Clin Diabetes*, 26(2): 77–82.
- Ge, M., Ryan, T.J., Lum, H., et al. 1991. "Fibrinogen degradation product fragment D increases endothelial monolayer permeability.". *AM J Physiol*, 261(4 Pt 1): L283–9.
- Geraldes, P. & King, G.L. 2010. "Activation of protein kinase C isoforms and its impact on diabetic complications". *Circ Res*, 106(8): 1319–1331.
- Di Giovine, G., Verdoia, M., Barbieri, L., et al. 2015. "Impact of diabetes on fibrinogen levels and its relationship with platelet reactivity and coronary artery disease: A single-centre study". *Diabetes Res Clin Pr*, 109(3): 541–550.
- Grassi, M.A., Tikhomirov, A., Ramalingam, S., et al. 2011. "Genome-wide meta-analysis for severe diabetic retinopathy". *Hum Mol Genet*, 20(12): 2472–2481.
- Greenberg, A.S. & Obin, M.S. 2006. "Obesity and the role of adipose tissue in inflammation and metabolism". *Am Journal of Clin Nutr*, 83(2): 461–465.
- Hammes, H.-P., Welp, R., Kempe, H.-P., et al. 2015. "Risk Factors for Retinopathy and DME in Type 2 Diabetes—Results from the German/Austrian DPV Database". *PLOS ONE*, 10(7): e0132492.
- Kimura, K., Orita, T., Kobayashi, Y., et al. 2017. "Concentration of acute phase factors in vitreous fluid in diabetic macular edema". *Jpn J Ophthalmol*, 61(6): 479–483.
- Kocabora, M.S., Telli, M.E., Fazil, K., et al. 2016. "Serum and Aqueous Concentrations of Inflammatory Markers in Diabetic Macular Edema". *Ocul Immunol Inflamm*, 24(5): 549–554
- Kuzhuppilly, N. & Pai, V. 2010. "Plasma fibrinogen levels and its relation to diabetic retinopathy". *Kerala J Ophthalmol XXII*(4): 339–345.
- Le, D.S.N.T., Miles, R., Savage, P.J., et al. 2008. "The association of plasma fibrinogen

- concentration with diabetic microvascular complications in young adults with early-onset of type 2 diabetes". *Diabetes Res Clin Pr*, 82(3): 317–323.
- Lee, R., Wong, T.Y. & Sabanayagam, C. 2015. "Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss". *Eye and Vision*, 2(1): 17.
- Lominadze, D., Tsakadze, N., Sen, U., et al. 2005. "Fibrinogen and fragment D-induced vascular constriction". , 40292: 1257–1264.
- Lopes de Faria, J.M., Jalkh, A.E., Trempe, C.L., et al. 1999. "Diabetic macular edema: risk factors and concomitants.". *Acta ophthalmol Scand*, 77(2): 170–175.
- Madonna, R., Balistreri, C.R., Geng, Y.J., et al. 2017. "Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches". *Vasc Pharmacol*, 90: 1–7.
- Mann, I., Kaur, R., Khan, B., et al. 2015. "Prevalence and causes of macular edema and its correlation : an observational study". *Annals of Applied Bio-Sciences*, 2(4): A111-116.
- Meleth, A.D., Agro'n, E., Chan, C.-C., et al. 2005. "Serum Inflammatory Markers in Diabetic Retinopathy". *Invest Ophthalmol Vis Sci*, 46(11): 4295.
- Mohan, G., Kaur, R., Aggarwal, A., et al. 2017. "To study levels of serum fibrinogen in type 2 diabetes mellitus and its association with diabetic microvascular". *International Journal of Advances in Medicine*, 4(1): 10–14.
- Mosesson, M.W. 2005. "Fibrinogen and fibrin structure and functions". *J Thromb Haemost*, 3: 1894–1904.
- Mota, S.E.H.-D., Soto-Bahena, J.J., Viveros-Sandoval, M.E., et al. 2015. "Pro-inflammatory serum cytokines in diabetic retinopathy". *Cir Cir (English Edition)*, 83(2): 100–106.
- Muradashvili, N., Qipshidze, N., Munjal, C., et al. 2012. "Fibrinogen-induced increased pial venular permeability in mice". *Journal of Cerebral Blood Flow and Metabolism*, 32(1): 150–163.
- Murugesan, N., Üstunkaya, T. & Feener, E.P. 2015. "Thrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an Inflammatory Standpoint". *Semin Thromb Hemost* 41(6): 659–664.
- Naruse, R., Suetsugu, M., Terasawa, T., et al. 2013. "Oxidative stress and antioxidative potency are closely associated with diabetic retinopathy and nephropathy in patients with type 2 diabetes". *Saudi Med J*, 34(2): 135–141.
- Nguyen, T.T., Alibrahim, E., Islam, F.M.A., et al. 2009. "Novel Biomarkers for Diabetic Retinopathy The Multi-Ethnic Study of Atherosclerosis". *Diabetes Care*,

32(9): 1704–9.

Olokoba, A.B., Obateru, O.A. & Olokoba, L.B. 2012. "Type 2 diabetes mellitus: A review of current trends". *Oman Med J*, 27(4): 269–273.

Ozkaya, A., Ozveren, M., Baz, O., et al. 2018. "Diabetic Macular Edema Patients with Poor Baseline Visual Acuity Treated with Ranibizumab in Real Life and Optical Coherence Tomography Based Predictor Factors for Visual Outcomes". *Nitte University Journal of Health Science*, 8(2): 8–12.

Panozzo, G., Parolini, B., Gusson, E., et al. 2004. "Diabetic macular edema: An OCT-based classification". *Semin Ophthalmol*, 19(1–2): 13–20.

Patibandla, P.K., Tyagi, N., Dean, W.L., et al. 2009. "Fibrinogen induces alterations of endothelial cell tight junction proteins". *J Cel Physiol*, 221(1): 195–203.

Payne, J.F., Ray, R., Watson, D.G., et al. 2012. "Vitamin D insufficiency in diabetic *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*,retinopathy.". 18(2): 185–93.

Provis, J.M., Penfold, P.L., Cornish, E.E., et al. 2005. "Anatomy and development of the macula: Specialisation and the vulnerability to macular degeneration". *Clin Exp Optom*, 88(5): 269–281.

Purushothaman, A. & Premaletha, T.K. 2016. "Plasma Fibrinogen Levels in Uncontrolled Diabetes Mellitus Abstract :". *IORS JDMS*, 15(12): 12–17.

Reijerkerk, A., Kooij, G., van der Pol, S.M.A., et al. 2006. "Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells.". *The FASEB journal*, 20(14): 2550–2552.

Romero-Aroca, P., Baget-Bernaldiz, M., Pareja-Rios, A., et al. 2016. "Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory". *J Diabetes Res*, 2016: 1–17.

Ruta, L.M., Magliano, D.J., Lemesurier, R., et al. 2013. "Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries.". *Diabet med*, 30(4): 387–398.

Saari, J.M., Summanen, P., Kivela, T., et al. 2004. "Sensitivity and specificity of digital retinal images in grading diabetic retinopathy". *Acta Ophthalmol Scand*, 82: 126–130.

Saboor, M. & Ilyas, S. 2012. "Platelets Structural , Functional and Metabolic Alterations in Diabetes Mellitus". *Pak J Physiol*, 8(2): 40–43.

Sahni, A., Arévalo, M.T., Sahni, S.K., et al. 2009. "The VE-cadherin binding domain

- of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of malignant breast epithelial cells.". *Int j cancer*, 125(3): 577–584.
- Salti, H.I., Nasrallah, M.P., Merheb, M., et al. 2006. "Elevated Body Mass Index is Associated With Higher Prevalence of Macular Edema in Patients With Type 2 Diabetes". *ARVO journal*, 47(13): 338.
- Sarelius, I.H. & Glading, A.J. 2015. "Control of vascular permeability by adhesion molecules". *Tissue Barriers*, 3(1–2): e985954.
- Sasongko, M.B., Widyaputri, F., Agni, A.N., et al. 2017. "Prevalence of Diabetic Retinopathy and Blindness in Indonesian Adults With Type 2 Diabetes". *Am J Ophthalmol*, 181: 79–87.
- Shea, S., Isasi, C.R., Couch, S., et al. 1999. "Relations of Plasma Fibrinogen Level in Children to Measures of Obesity, the (G-455 A) Mutation in the -Fibrinogen Promoter Gene, and Family History of Ischemic Heart Disease: The Columbia University BloMarkers Study". *Am J Epidemiol*, 150(7): 737–746.
- Staurengi, G., Sadda, S., Chakravarthy, U., et al. 2014. "Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: The IN•OCT consensus". *Ophthalmology*, 121(8): 1572–1578.
- Stefánsson, E. 2009. "Diabetic macular edema". *Saudi J Ophthalmol*, 23(2): 143–148.
- Stratmann, B. & Tschoepe, D. 2005. "Pathobiology and cell interactions of platelets in diabetes". *Diab Vasc Dis Res*, 2(1): 16–23.
- Tan, G.S., Cheung, N., Simó, R., et al. 2017. "Diabetic macular oedema". *The Lancet Diabetes Endocrinol*, 5(2): 143–155.
- Targher, G., Bertolini, L., Zoppini, G., et al. 2005. "Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy". *Diabet Med*, 22(8): 999–1004.
- Tarr, J.M., Kaul, K., Chopra, M., et al. 2013. "Pathophysiology of Diabetic Retinopathy". *ISRN Ophthalmology*, 2013: 1–13.
- Tennent, G. a, Brennan, S.O., Stangou, A.J., et al. 2007. "Human plasma fibrinogen is synthesized in the liver". *Blood*, 109(5): 1971–1974.
- Tsakiri, N., Kimber, I., Rothwell, N.J., et al. 2008. "Mechanisms of interleukin-6 synthesis and release induced by interleukin-1 and cell depolarisation in neurones". *Mol Cell Neurosci*, 37(1): 110–118.

- Tyagi, N., Roberts, A.F., Dean, W.L., et al. 2008. "Fibrinogen induces endothelial cell permeability". *Mol Cell Biochem*, 27(4): 339–351.
- Varma, R., Bressler, N.M., Doan, Q. V., et al. 2014. "Prevalence of and risk factors for diabetic macular edema in the United States". *JAMA Ophthalmol*, 132(11): 1334–1340.
- Versteeg, H.H., Heemskerk, J.W.M., Levi, M., et al. 2013. "New Fundamentals in Hemostasis". *Physiol Rev*, 93(1): 327–358.
- Weisel, J.W. & Medved, L. 2005. "Fibrinogen and Fibrin". *Adv Protein Chem*, 70(04): 247–299.
- White, N.H., Sun, W., Cleary, P. a, et al. 2010. "Effect of Prior Intensive Therapy in Type 1 Diabetes on 10-Year Progression of Retinopathy in the DCCT / EDIC : Comparison of Adults and Adolescents". *Diabetes*, 59(5): 1244–53.
- Wild Sarah, Roglic Gojka, Green Anders, et al. 2004. "Global Prevalence of Diabetes: Estimates for the year 2000 and projection for 2030". *Diabetes Care*, 27(5): 1047–1053.
- World Health Organization. 2016. "Global Report on Diabetes". *Isbn*, 978: 88.
- Yau, J.W.Y., Rogers, S.L., Kawasaki, R., et al. 2012. "Global Prevalence and Major Risk Factors of Diabetic Retinopathy". *Diabetes Care*, 35(3): 556–564.
- Zhang, X., Zeng, H., Bao, S., et al. 2014. "Diabetic macular edema: new concepts in patho-physiology and treatment". *Cell Biosci*, 4(1): 27.
- Zhong, Z.-L., Han, M. & Chen, S. 2011. "Risk factors associated with retinal neovascularization of diabetic retinopathy in type 2 diabetes mellitus". *Int J Ophthalmol*, 4(2): 182–185.
- Ziyyat, A., Ramdani, N., Bouanani, N. El, et al. 2014. "Epidemiology of hypertension and its relationship with type 2 diabetes and obesity in eastern Morocco". *SpringerPlus*, 3(1): 644.